Clínica Médica
Principais estudos de 2021 relevantes para a atenção primária.
27 Mai, 2022 | 13:47hTop studies of 2021 relevant to primary care: From the PEER team – Canadian Family Physician
Estudo relata primeiro uso de antivirais em pacientes com varíola dos macacos.
27 Mai, 2022 | 13:45hComunicado de imprensa: Study reports first use of antivirals in monkeypox patients – Lancet
Estudo original: Clinical features and management of human monkeypox: a retrospective observational study in the UK – The Lancet Infectious Diseases
Comentário: Antiviral drug may limit monkeypox symptom duration, infectiousness – CIDRAP
Comentário de um dos autores no Twitter (fio – clique para saber mais)
Clinical features and management of human monkeypox: a retrospective observational study in the UK https://t.co/0nUtw3lEDn
— Jake Dunning (@OutbreakJake) May 24, 2022
Comentário de estudo | Grande estudo mostra que risco de COVID longa diminui apenas discretamente após a vacinação.
27 Mai, 2022 | 13:44hComentário: Long COVID risk falls only slightly after vaccination, huge study shows – Nature
Estudo original: Long COVID after breakthrough SARS-CoV-2 infection – Nature Medicine
Comentário do autor no Twitter (fio – clique para saber mais)
The latest from our team in @NatureMedicine
Does vaccination protect from #LongCovid?
Vaccines modestly reduce but do not eliminate risk of Long Covid @VAResearch @vahsrd @WUSTLmed @WUSTLnews @VREFSTL@Biostayan @BCBowe https://t.co/UEexmL8svS
A thread 🧵
— Ziyad Al-Aly, MD (@zalaly) May 25, 2022
Estudo de coorte | Trajetória dos sintomas de Covid longa após vacinação contra Covid-19.
27 Mai, 2022 | 13:41hTrajectory of long covid symptoms after covid-19 vaccination: community based cohort study – The BMJ
Editorial: Are vaccines a potential treatment for long covid? – The BMJ
Comunicado de imprensa: Vaccination after SARS-CoV-2 infection linked to a decrease in long covid symptoms – BMJ Newsroom
Comentário no Twitter
LONG COVID: Number of well controlled studies (controls means comparison group of 1) unvaccinated and 2) those who have never had COVID) that show vaccination works to reduce or eliminate long COVID symptoms increasing. BMJ below + biggest from Israel herehttps://t.co/jtZ6aoDmFA https://t.co/n5oDs0Zxe9
— Monica Gandhi MD, MPH (@MonicaGandhi9) May 19, 2022
Estudo de coorte | Proteção e queda da imunidade natural e híbrida ao SARS-CoV-2.
27 Mai, 2022 | 13:39hProtection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Editorial: Audio Interview: Waning Immunity against Covid-19
Comentário no Twitter
Protection against SARS-CoV-2 waned over time in both vaccinated and previously infected persons; an additional vaccine dose restored protection, find investigators from Israel. https://t.co/617uBmWu8l pic.twitter.com/yiDnBbCuQ5
— NEJM (@NEJM) May 25, 2022
Estudo de caso-controle e teste negativo: efetividade dos reforços vacinais homólogos e heterólogos contra a variante Ômicron da COVID-19.
27 Mai, 2022 | 13:38hRevisão de escopo | Caracterização e quantificação internacional de diagnóstico por imagem de baixo valor.
27 Mai, 2022 | 13:34hDiretriz sobre intervenções para melhorar a cicatrização de úlceras no pé diabético.
27 Mai, 2022 | 13:32hRevisão sistemática | Tratamento para sialorreia em pessoas com esclerose lateral amiotrófica/doença do neurônio motor.
27 Mai, 2022 | 13:20hResumo: Treatment of unintentional drooling of saliva in motor neuron disease – Cochrane Library
M-A | Tratamento do diabetes tipo 2 com tirzepatida, um agonista duplo do receptor de GIP/GLP-1.
27 Mai, 2022 | 13:13hConteúdos relacionados:
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)